● Home  

● Random  

● Nearby  



● Log in  



● Settings  



● Donate  



● About Wikipedia  

● Disclaimers  



Wikipedia





MK-4409





● Article  
● Talk  


● Language  

● Watch  

● Edit  





MK-4409 is an experimental drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 11 nM, and both analgesic and antiinflammatory effects in animal studies. It was studied for the treatment of neuropathic pain and progressed to early stage human clinical trials by 2009.[1][2]

MK-4409
Clinical data
ATC code
  • None
Legal status
Legal status
Identifiers

  • 2-[5-[5-(5-Chloropyridin-2-yl)sulfanyl-2-(4-fluorophenyl)-1,3-oxazol-4-yl]pyridin-2-yl]propan-2-ol

CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H17FN3O2S
Molar mass406.46 g·mol−1
3D model (JSmol)

  • c3nc(C(O)(C)C)ccc3-c1nc(-c4ccc(F)cc4)oc1Sc(nc2)ccc2Cl

  • InChI=1S/C22H17ClFN3O2S/c1-22(2,28)17-9-5-14(11-25-17)19-21(30-18-10-6-15(23)12-26-18)29-20(27-19)13-3-7-16(24)8-4-13/h3-12,28H,1-2H3

  • Key:DBZMCSVIITXLCC-UHFFFAOYSA-N

See also

edit

References

edit
  1. ^ Chobanian HR, Guo Y, Liu P, Chioda MD, Fung S, Lanza TJ, et al. (June 2014). "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Medicinal Chemistry Letters. 5 (6): 717–21. doi:10.1021/ml5001239. PMC 4060928. PMID 24944750.
  • ^ Merck (15 October 2009). "Merck Pipeline, Oct 2009" (PDF). Merck. Archived from the original (PDF) on 20 October 2016. Retrieved 18 January 2016.
    • edit

    Retrieved from "https://en.wikipedia.org/w/index.php?title=MK-4409&oldid=1190947802"
      



    Last edited on 20 December 2023, at 19:50  





    Languages

     



    This page is not available in other languages.
      

     Wikipedia


    ●This page was last edited on 20 December 2023, at 19:50 (UTC).
    ●Content is available under CC BY-SA 4.0 unless otherwise noted.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Terms of Use
    ●Desktop